The use of HER2 modulation in the adjuvant setting
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Amplification of theher-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.
- Jemal AR, Siegel E, Ward, et al.:Cancer statistics, 2006.CA Cancer J Clin 2006,56:106–130. CrossRef
- Gschwind A, Fischer OM, Ullrich A:The discovery of receptor tyrosine kinases: targets for cancer therapy.Nat Rev Cancer 2004,4:361–370. CrossRef
- Slamon DJ, Clark GM, Wong SG, et al.:Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 1987,235:177–182. CrossRef
- Slamon DJ, Godolphin W, Jones LA, et al.:Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 1989,244:707–712. CrossRef
- Carter P, Presta L, Gorman CM, et al.:Humanization of an anti-p185HER2 antibody for human cancer therapy.Proc Natl Acad Sci U S A 1992,89:4285–4289. CrossRef
- Slamon DJ, Leyland-Jones B, Shak S, et al.:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 2001,344:783–792. CrossRef
- Marty M, Cognetti F, Maraninchi D, et al.:Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.J Clin Oncol 2005,23:4265–4274. CrossRef
- Vogel CL., Cobleigh MA, Tripathy D, et al.:Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol 2002,20:719–726. CrossRef
- Baselga J, Carbonell X, Castaneda-Soto NJ, et al.:Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.J Clin Oncol 2005,23:2162–2171. CrossRef
- Romond EH, Perez EA, Bryant J, et al.:Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med 2005,353:1673–1684. CrossRef
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.:Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med 2005,353:1659–1672. CrossRef
- Slamon D, Eiermann W, Robert N, et al.:Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005,94:S5a.
- Joensuu H, Joensuu K.-L.P.-L., Bono P, et al.:Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial.N Engl J Med 2006,354:809–820. CrossRef
- Perez E:Special session: Monoclonal antibody therapy in breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005.
- Smith IE, on behalf of the HERA study team: Scientificspecial session: Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Presented at the American Society of Clinical Oncology Annual Meeting; 2006.
- Pegram M, Hsu S, Lewis G, et al.:Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene 1999,18:2241–2251. CrossRef
- Pegram, MD, O’Callaghan C:Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.Clin Breast Cancer 2001,2(Suppl 1):S15-S19. CrossRef
- Pegram MD, Lopez A, Konecny G, Slamon DJ:Trastuzumab and chemotherapeutics: drug interactions and synergies.Semin Oncol 2000,27:21–25; discussion 92–100.
- Hortobagyi GN:Trastuzumab in the treatment of breast cancer.N Engl J Med 2005,353:1734–1736. CrossRef
- Bendell JC, Domchek SM, Burstein HJ, et al.:Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer 2003,97:2972–2977. CrossRef
- Hurley, J, Doliny P, Reis I, et al.:Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.J Clin Oncol 2006,24:1831–1838. CrossRef
- Buzdar AU, Ibrahim NK, Francis D, et al.:Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol 2005,23:3676–3685. CrossRef
- Seidman A, Hudis C, Pierri MK, et al.:Cardiac dysfunction in the trastuzumab clinical trials experience.J Clin Oncol 2002,20:1215–1221. CrossRef
- Perez EA, Rodeheffer R:Clinical cardiac tolerability of trastuzumab.J Clin Oncol 2004,22:322–329. CrossRef
- Tan-Chiu E, Yothers G, Romond E, et al.:Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.J Clin Oncol 2005,23:7811–7819. CrossRef
- Crone SA, Zhao YY, Fan L, et al.:ErbB2 is essential in the prevention of dilated cardiomyopathy.Nat Med 2002,8:459–465. CrossRef
- Chien KR:Herceptin and the heart—a molecular modifier of cardiac failure.N Engl J Med 2006,354:789–790. CrossRef
- Guarneri V, Lenihan D, Valero V, et al.:Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.J Clin Oncol 200624:4107–4115. CrossRef
- The use of HER2 modulation in the adjuvant setting
Current Oncology Reports
Volume 9, Issue 1 , pp 9-16
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links